Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
NEW YORK--(BUSINESS WIRE)--Apr 29, 2024--
Stay updated with breaking news from Der Heijden. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK--(BUSINESS WIRE)--Apr 29, 2024--
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.
Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.
Judith van Der Heijden, Chief Concierge at one of London's most luxurious hotels in Covent Garden, shared all in a quick-fire video featured on TikTok by AJX media.